Overall, results of the completed studies utilizing CSF-1R inhibitors suggest that combination of these biologically active drugs with anti-PD-1 therapy alone is insufficient to produce significant anti-tumor activity in advanced PDAC. Here, CSF1R is linked to neoplasm.